Report cover image

Global PDGFR Inhibitors Market Growth (Status and Outlook) 2024-2030

Publisher LP Information, Inc.
Published Aug 09, 2024
Length 91 Pages
SKU # LPI19066663

Description

Global PDGFR Inhibitors Market Growth (Status and Outlook) 2024-2030


The FDA has approved more than 10 PDGFR multikinase antagonists for the treatment of various tumor diseases and pulmonary fibrosis. Recombinant PDGF is used to help treat chronic ulcers, orthopedic surgery and periodontal disease to stimulate bone regeneration and repair. When PDGF is used alone or in combination with other growth factors to stimulate soft and hard tissue healing.

The global PDGFR Inhibitors market size is projected to grow from US$ 2424 million in 2024 to US$ 3735 million in 2030; it is expected to grow at a CAGR of 7.5% from 2024 to 2030.

LPI (LP Information)' newest research report, the “PDGFR Inhibitors Industry Forecast” looks at past sales and reviews total world PDGFR Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected PDGFR Inhibitors sales for 2023 through 2029. With PDGFR Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PDGFR Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global PDGFR Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PDGFR Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PDGFR Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PDGFR Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PDGFR Inhibitors.

United States market for PDGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for PDGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for PDGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key PDGFR Inhibitors players cover Novartis, Eli Lilly, Eisai, Pfizer, GSK, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of PDGFR Inhibitors market by product type, application, key players and key regions and countries.

Segmentation by Type:
Capsules
Tablets
Others

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Capsules
Tablets
Others

Segmentation by Application:
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Eli Lilly
Eisai
Pfizer
GSK
Boehringer Ingelheim
Il-Yang Pharmaceutical
Takeda
Bayer
Bristol-Myers Squibb

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

91 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PDGFR Inhibitors Market Size 2019-2030
2.1.2 PDGFR Inhibitors Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for PDGFR Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 PDGFR Inhibitors Segment by Type
2.2.1 Capsules
2.2.2 Tablets
2.2.3 Others
2.3 PDGFR Inhibitors Market Size by Type
2.3.1 PDGFR Inhibitors Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global PDGFR Inhibitors Market Size Market Share by Type (2019-2024)
2.4 PDGFR Inhibitors Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.5 PDGFR Inhibitors Market Size by Application
2.5.1 PDGFR Inhibitors Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global PDGFR Inhibitors Market Size Market Share by Application (2019-2024)
3 PDGFR Inhibitors Market Size by Player
3.1 PDGFR Inhibitors Market Size Market Share by Player
3.1.1 Global PDGFR Inhibitors Revenue by Player (2019-2024)
3.1.2 Global PDGFR Inhibitors Revenue Market Share by Player (2019-2024)
3.2 Global PDGFR Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PDGFR Inhibitors by Region
4.1 PDGFR Inhibitors Market Size by Region (2019-2024)
4.2 Global PDGFR Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas PDGFR Inhibitors Market Size Growth (2019-2024)
4.4 APAC PDGFR Inhibitors Market Size Growth (2019-2024)
4.5 Europe PDGFR Inhibitors Market Size Growth (2019-2024)
4.6 Middle East & Africa PDGFR Inhibitors Market Size Growth (2019-2024)
5 Americas
5.1 Americas PDGFR Inhibitors Market Size by Country (2019-2024)
5.2 Americas PDGFR Inhibitors Market Size by Type (2019-2024)
5.3 Americas PDGFR Inhibitors Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PDGFR Inhibitors Market Size by Region (2019-2024)
6.2 APAC PDGFR Inhibitors Market Size by Type (2019-2024)
6.3 APAC PDGFR Inhibitors Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe PDGFR Inhibitors Market Size by Country (2019-2024)
7.2 Europe PDGFR Inhibitors Market Size by Type (2019-2024)
7.3 Europe PDGFR Inhibitors Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PDGFR Inhibitors by Region (2019-2024)
8.2 Middle East & Africa PDGFR Inhibitors Market Size by Type (2019-2024)
8.3 Middle East & Africa PDGFR Inhibitors Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global PDGFR Inhibitors Market Forecast
10.1 Global PDGFR Inhibitors Forecast by Region (2025-2030)
10.1.1 Global PDGFR Inhibitors Forecast by Region (2025-2030)
10.1.2 Americas PDGFR Inhibitors Forecast
10.1.3 APAC PDGFR Inhibitors Forecast
10.1.4 Europe PDGFR Inhibitors Forecast
10.1.5 Middle East & Africa PDGFR Inhibitors Forecast
10.2 Americas PDGFR Inhibitors Forecast by Country (2025-2030)
10.2.1 United States Market PDGFR Inhibitors Forecast
10.2.2 Canada Market PDGFR Inhibitors Forecast
10.2.3 Mexico Market PDGFR Inhibitors Forecast
10.2.4 Brazil Market PDGFR Inhibitors Forecast
10.3 APAC PDGFR Inhibitors Forecast by Region (2025-2030)
10.3.1 China PDGFR Inhibitors Market Forecast
10.3.2 Japan Market PDGFR Inhibitors Forecast
10.3.3 Korea Market PDGFR Inhibitors Forecast
10.3.4 Southeast Asia Market PDGFR Inhibitors Forecast
10.3.5 India Market PDGFR Inhibitors Forecast
10.3.6 Australia Market PDGFR Inhibitors Forecast
10.4 Europe PDGFR Inhibitors Forecast by Country (2025-2030)
10.4.1 Germany Market PDGFR Inhibitors Forecast
10.4.2 France Market PDGFR Inhibitors Forecast
10.4.3 UK Market PDGFR Inhibitors Forecast
10.4.4 Italy Market PDGFR Inhibitors Forecast
10.4.5 Russia Market PDGFR Inhibitors Forecast
10.5 Middle East & Africa PDGFR Inhibitors Forecast by Region (2025-2030)
10.5.1 Egypt Market PDGFR Inhibitors Forecast
10.5.2 South Africa Market PDGFR Inhibitors Forecast
10.5.3 Israel Market PDGFR Inhibitors Forecast
10.5.4 Turkey Market PDGFR Inhibitors Forecast
10.6 Global PDGFR Inhibitors Forecast by Type (2025-2030)
10.7 Global PDGFR Inhibitors Forecast by Application (2025-2030)
10.7.1 GCC Countries Market PDGFR Inhibitors Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis PDGFR Inhibitors Product Offered
11.1.3 Novartis PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly PDGFR Inhibitors Product Offered
11.2.3 Eli Lilly PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Eisai
11.3.1 Eisai Company Information
11.3.2 Eisai PDGFR Inhibitors Product Offered
11.3.3 Eisai PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Eisai Main Business Overview
11.3.5 Eisai Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer PDGFR Inhibitors Product Offered
11.4.3 Pfizer PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 GSK
11.5.1 GSK Company Information
11.5.2 GSK PDGFR Inhibitors Product Offered
11.5.3 GSK PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 GSK Main Business Overview
11.5.5 GSK Latest Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim PDGFR Inhibitors Product Offered
11.6.3 Boehringer Ingelheim PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Boehringer Ingelheim Main Business Overview
11.6.5 Boehringer Ingelheim Latest Developments
11.7 Il-Yang Pharmaceutical
11.7.1 Il-Yang Pharmaceutical Company Information
11.7.2 Il-Yang Pharmaceutical PDGFR Inhibitors Product Offered
11.7.3 Il-Yang Pharmaceutical PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Il-Yang Pharmaceutical Main Business Overview
11.7.5 Il-Yang Pharmaceutical Latest Developments
11.8 Takeda
11.8.1 Takeda Company Information
11.8.2 Takeda PDGFR Inhibitors Product Offered
11.8.3 Takeda PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Takeda Main Business Overview
11.8.5 Takeda Latest Developments
11.9 Bayer
11.9.1 Bayer Company Information
11.9.2 Bayer PDGFR Inhibitors Product Offered
11.9.3 Bayer PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Bayer Main Business Overview
11.9.5 Bayer Latest Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Information
11.10.2 Bristol-Myers Squibb PDGFR Inhibitors Product Offered
11.10.3 Bristol-Myers Squibb PDGFR Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Bristol-Myers Squibb Main Business Overview
11.10.5 Bristol-Myers Squibb Latest Developments
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us